首页> 美国卫生研究院文献>Aging (Albany NY) >Identification of regulation of RhoA activity panel as a prognostic and predictive biomarker for gastric cancer
【2h】

Identification of regulation of RhoA activity panel as a prognostic and predictive biomarker for gastric cancer

机译:鉴定RHOA活性小组调节作为胃癌预测和预测生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

RhoA is a member of the RHO family GTPases and is associated with essential functions in gastric cancer. In this study, we identified a gastric cancer biomarker, termed the “regulation of RhoA activity panel” (RRAP). Patients with gastric cancer from The Cancer Genome Atlas database were divided into training (N=160) and validation (N=155) cohorts. A cohort of 109 Chinese gastric cancer patients was utilized as an independent validation. Patients with mutated RRAP showed significantly better overall survival than patients with wild type RRAP. We also analyzed the association between RRAP and the migration capacity, immune-related signatures, and the tumor microenvironment. RRAP-mutant tumors had a significantly lower degree of lymph node metastasis and lower activities of migration-related pathways. These tumors also showed significantly increased immune cell infiltration and cytotoxic activity. Furthermore, two independent patient cohorts who received immune checkpoint blockade therapy were assessed for RRAP mutant status. As expected, for both immunotherapy cohorts, higher response rates to immune checkpoint blockade therapy were observed in patients with RRAP-mutant tumors than in patients with wild type RRAP tumors. Overall, this study indicates that the RRAP gene set is a potential biomarker for gastric cancer prognosis and therapeutic selection.
机译:RhoA是Rho家族GTP酶的成员,与胃癌中的基本功能有关。在这项研究中,我们鉴定了一种胃癌生物标志物,称为“RHOA活性面板的调节”(RRAP)。来自癌症基因组数据库的胃癌患者分为训练(n = 160)和验证(n = 155)群。 109例中国胃癌患者的群组被用作独立验证。突变的RRAP患者显示出比野生型RRAP的患者显着更好地生存。我们还分析了RRAP与迁移能力,免疫相关签名和肿瘤微环境之间的关联。 RRAP-突变肿瘤具有明显较低程度的淋巴结转移和迁移相关途径的较低活动。这些肿瘤还显示出显着提高免疫细胞浸润和细胞毒性活性。此外,对RRAP突变体状态评估了接受免疫检查点阻断疗法的两个独立患者群体。正如预期的那样,对于免疫治疗队列,在RRAP-突变肿瘤的患者中观察到免疫检查点阻断治疗的更高的反应率,而不是野生型RRAP肿瘤的患者。总体而言,该研究表明RRAP基因组是胃癌预后和治疗选择的潜在生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号